GSK · story · 22 October – 24 October
GSK · 6 headlines from 6 outlets, from 22 October 2026 to 24 October 2026.
CSL named ViiV CEO Deborah Waterhouse as its next CEO.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Fierce Biotech is the largest at 1.7, ahead of Pharmaceutical Executive (−3.3). Bloomberg is the lowest at −5.0. 5 of the 6 are below zero.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Bloomberg | −5.0 |
| Endpoints News | −5.0 |
| Fierce Pharma | −4.2 |
| 95.7 KELO-FM | −4.2 |
| Pharmaceutical Executive | −3.3 |
| Fierce Biotech | 1.7 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Bloomberg | 1 | −5.0 |
| Endpoints News | 1 | −5.0 |
| Fierce Pharma | 1 | −4.2 |
| 95.7 KELO-FM | 1 | −4.2 |
| Pharmaceutical Executive | 1 | −3.3 |
| Fierce Biotech | 1 | +1.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +1.7 | Former GSK executive appointed CSL chief; minor reputational note. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| −5.0 | ViiV CEO departing to rival CSL; leadership loss. |
| −5.0 | ViiV CEO leaves for CSL after three decades. |
| −4.2 | Senior GSK executive poached by CSL. |
| −4.2 | GSK executive named CSL CEO. |
| −3.3 | CSL appoints GSK's Waterhouse; leadership departure. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.